# Secukinumab, an Interleukin-17A Inhibitor, in Ankylosi

New England Journal of Medicine
373, 2534-2548
DOI: 10.1056/nejmoa1505066

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | New immune cells in spondyloarthritis: Key players or innocent bystanders?. Best Practice and Research in Clinical Rheumatology, 2015, 29, 706-714. | 1.4 | 17 |
| 2 | Secukinumab for ankylosing spondylitis and psoriatic arthritis. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1587-1592. | 0.9 | 39 |
| 3 | A New Era in Psoriasis and Psoriatic Arthritis Therapy: Drugs with New Mechanism of Action and the Option for the use Biosimilars. Journal of Clinical & Experimental Dermatology Research, 2016, 07, . | 0.1 | 0 |
| 4 | Drugs That Act on the Immune System. Side Effects of Drugs Annual, 2016, , 395-405. | 0.6 | 1 |
| 5 | Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. International Journal of Cell Biology, 2016, 2016, 1-11. | 1.0 | 156 |
| 6 | Secukinumab for rheumatology: development and its potential place in therapy. Drug Design, Development and Therapy, 2016, Volume 10, 2069-2080. | 2.0 | 37 |
| 7 | Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab. Clinical, Cosmetic and Investigational Dermatology, 2016, Volume 9, 347-355. | 0.8 | 11 |
| 8 | Targeting the interleukin-23/17 axis in axial spondyloarthritis. Current Opinion in Rheumatology, 2016, 28, 359-367. | 2.0 | 44 |
| 9 | Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update. American Journal of Clinical Dermatology, 2016, 17, 425-443. | 3.3 | 37 |
| 10 | Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Research and Therapy, 2016, 18, 275. | 1.6 | 40 |
| 11 | Fungal Infections and New Biologic Therapies. Current Rheumatology Reports, 2016, 18, 29. | 2.1 | 87 |
| 12 | Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatology and Therapy, 2016, 3, 5-29. | 1.1 | 47 |
| 13 | Killer immunoglobulin receptor genes in spondyloarthritis. Current Opinion in Rheumatology, 2016, 28, 368-375. | 2.0 | 7 |
| 14 | New evidence on the management of spondyloarthritis. Nature Reviews Rheumatology, 2016, 12, 282-295. | 3.5 | 104 |
| 15 | Increased sensitivity of rheumatoid synoviocytes to Schnurri-3 expression in TNF-Î± and IL-17A induced osteoblastic differentiation. Bone, 2016, 87, 89-96. | 1.4 | 27 |
| 16 | The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis. Current Rheumatology Reports, 2016, 18, 33. | 2.1 | 7 |
| 17 | Ankylosing spondylitis: beyond genome-wide association studies. Current Opinion in Rheumatology, 2016, 28, 337-345. | 2.0 | 22 |
| 18 | Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis. Journal of Rheumatology, 2016, 43, 1695-1703. | 1.0 | 80 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis. Current Rheumatology Reports, 2016, 18, 63. | 2.1 | 6 |
| 21 | Safety of secukinumab in the treatment of psoriasis. Expert Opinion on Drug Safety, 2016, 15, 1413-1420. | 1.0 | 99 |
| 22 | Secukinumab for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 1027-1036. | 1.3 | 7 |
| 23 | Effect of Secukinumab on Patientâ€Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Arthritis and Rheumatology, 2016, 68, 2901-2910. | 2.9 | 63 |
| 24 | Secukinumab: a promising therapeutic option in spondyloarthritis. Clinical Rheumatology, 2016, 35, 2151-2161. | 1.0 | 2 |
| 26 | Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFÎ± neutralization. Scientific Reports, 2016, 6, 36923. | 1.6 | 34 |
| 27 | New treatment targets for axial spondyloarthritis: Table 1. Rheumatology, 2016, 55, ii38-ii42. | 0.9 | 21 |
| 28 | Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. Current Rheumatology Reports, 2016, 18, 72. | 2.1 | 10 |
| 29 | Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-Î± and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis. Rheumatology and Therapy, 2016, 3, 323-336. | 1.1 | 12 |
| 31 | Secukinumab: A Review in Ankylosing Spondylitis. Drugs, 2016, 76, 1023-1030. | 4.9 | 35 |
| 32 | Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney International, 2016, 90, 515-524. | 2.6 | 138 |
| 33 | Unintended Immunological Consequences of Biologic Therapy. Current Allergy and Asthma Reports, 2016, 16, 46. | 2.4 | 18 |
| 34 | Biologic agents in juvenile spondyloarthropathies. Pediatric Rheumatology, 2016, 14, 17. | 0.9 | 21 |
| 35 | Secukinumab: A Review in Psoriatic Arthritis. Drugs, 2016, 76, 1135-1145. | 4.9 | 25 |
| 36 | Ankylosing Spondylitis and Axial Spondyloarthritis. New England Journal of Medicine, 2016, 374, 2563-2574. | 13.9 | 565 |
| 37 | IL-17A blockade ameliorates ankylosing spondylitis. Nature Reviews Rheumatology, 2016, 12, 72-72. | 3.5 | 11 |
| 38 | Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy, 2016, 16, 711-722. | 1.4 | 22 |
| 39 | Is There a Future for Interleukin 17 Blocking Agents in Rheumatoid Arthritis?. Journal of Rheumatology, 2016, 43, 465-467. | 1.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 40 | CCAAT/Enhancer-binding protein Î² promotes pathogenesis of EAE. Cytokine, 2017, 92, 24-32. | 1.4 | 52 |
| 41 | New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Expert Opinion on Pharmacotherapy, 2017, 18, 275-282. | 0.9 | 8 |
| 42 | Axial spondyloarthritis. Lancet, The, 2017, 390, 73-84. | 6.3 | 876 |
| 43 | Recomendaciones del Grupo EspaÃ±ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con espondiloartritis asociada a enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal Al DÃa, 2017, 16, 1-14. | 0.2 | 0 |
| 44 | Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases. Nature Reviews Rheumatology, 2017, 13, 164-173. | 3.5 | 69 |
| 45 | miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis. Annals of the Rheumatic Diseases, 2017, 76, 620-625. | 0.5 | 61 |
| 46 | Review: Innate Lymphoid Cells: Sparking Inflammatory Rheumatic Disease?. Arthritis and Rheumatology, 2017, 69, 885-897. | 2.9 | 13 |
| 47 | Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies. Current Rheumatology Reports, 2017, 19, 8. | 2.1 | 8 |
| 48 | Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the Rheumatic Diseases, 2017, 76, 1070-1077. | 0.5 | 213 |
| 49 | Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases, 2017, 76, 1340-1347. | 0.5 | 287 |
| 51 | Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Annals of the Rheumatic Diseases, 2017, 76, 571-592. | 0.5 | 137 |
| 52 | Biologic Therapies for Autoimmune and Connective Tissue Diseases. Immunology and Allergy Clinics of North America, 2017, 37, 283-299. | 0.7 | 24 |
| 53 | Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?. Current Rheumatology Reports, 2017, 19, 14. | 2.1 | 18 |
| 54 | Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Research and Therapy, 2017, 19, 51. | 1.6 | 58 |
| 55 | Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. Arthritis Care and Research, 2017, 69, 1020-1029. | 1.5 | 79 |
| 56 | Editorial: Choosing New Targets for Rheumatoid Arthritis Therapeutics: Too Interesting to Fail?. Arthritis and Rheumatology, 2017, 69, 1131-1134. | 2.9 | 4 |
| 57 | Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD Open, 2017, 3, e000284. | 1.8 | 76 |
| 58 | 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991. | 0.5 | 1,220 |

| # | Article | IF | Citations |
|---|---|---|---|
| 59 | Biologic response modifiers: Indications, implications, and insights. Journal of Allergy and Clinical Immunology, 2017, 139, 1445-1456. | 1.5 | 25 |
| 60 | Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain BarrÃ© syndrome after anti-TNF-Î± treatment? Case report and literature review. Clinical Rheumatology, 2017, 36, 1197-1199. | 1.0 | 9 |
| 61 | Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open, 2017, 3, e000396. | 1.8 | 99 |
| 62 | The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion. Molecular and Cellular Proteomics, 2017, 16, 642-662. | 2.5 | 50 |
| 63 | Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis. Current Opinion in Rheumatology, 2017, 29, 287-292. | 2.0 | 25 |
| 64 | Silicone breast implants and autoimmune rheumatic diseases: myth or reality. Current Opinion in Rheumatology, 2017, 29, 348-354. | 2.0 | 70 |
| 65 | Human papilloma virus and lupus: the virus, the vaccine and the disease. Current Opinion in Rheumatology, 2017, 29, 331-342. | 2.0 | 40 |
| 66 | Body composition assessment in the prediction of osteoporotic fractures. Current Opinion in Rheumatology, 2017, 29, 394-401. | 2.0 | 17 |
| 67 | Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis. Therapeutic Drug Monitoring, 2017, 39, 360-363. | 1.0 | 8 |
| 68 | Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis. Journal of Molecular Medicine, 2017, 95, 779-787. | 1.7 | 19 |
| 69 | Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Review of Clinical Pharmacology, 2017, 10, 899-910. | 1.3 | 34 |
| 70 | The field of spondyloarthritis coming of age. Current Opinion in Rheumatology, 2017, 29, 285-286. | 2.0 | 0 |
| 71 | Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2017, 47, 343-350. | 1.6 | 68 |
| 73 | Interleukin 17 is a chief orchestrator of immunity. Nature Immunology, 2017, 18, 612-621. | 7.0 | 375 |
| 74 | Developments in therapy with monoclonal antibodies and related proteins. Clinical Medicine, 2017, 17, 220-232. | 0.8 | 137 |
| 76 | Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. Journal of Dermatology, 2017, 44, 1105-1111. | 0.6 | 13 |
| 77 | Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52â€week pooled results from two phase 3 studies. International Journal of Rheumatic Diseases, 2017, 20, 589-596. | 0.9 | 28 |
| 78 | Developments with experimental and investigational drugs for axial spondyloarthritis. Expert Opinion on Investigational Drugs, 2017, 26, 833-842. | 1.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 79 | Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) â€“ an open-label randomized controlled multicenter trial. BMJ Open, 2017, 7, e014591. | 0.8 | 17 |
| 80 | Pain in ankylosing spondylitis: a neuro-immune collaboration. Nature Reviews Rheumatology, 2017, 13, 410-420. | 3.5 | 54 |
| 81 | Cryoglobulinemia vasculitis: how to handle. Current Opinion in Rheumatology, 2017, 29, 343-347. | 2.0 | 17 |
| 82 | Tracking JAKs in spondyloarthritis: rationale and expectations. Annals of the Rheumatic Diseases, 2017, 76, 1325-1326. | 0.5 | 5 |
| 83 | Follistatinâ€like protein 1 modulates ILâ€17 signaling via ILâ€17RC regulation in stromal cells. Immunology and Cell Biology, 2017, 95, 656-665. | 1.0 | 11 |
| 84 | The gut microbiota: a possible factor influencing systemic lupus erythematosus. Current Opinion in Rheumatology, 2017, 29, 374-377. | 2.0 | 56 |
| 85 | Chikungunya virus and autoimmunity. Current Opinion in Rheumatology, 2017, 29, 389-393. | 2.0 | 32 |
| 86 | New developments in uveitis associated with HLA B27. Current Opinion in Rheumatology, 2017, 29, 298-303. | 2.0 | 39 |
| 87 | Treat to Target in Axial Spondyloarthritis: What Are the Issues?. Current Rheumatology Reports, 2017, 19, 22. | 2.1 | 17 |
| 88 | From microbiome to infectome in autoimmunity. Current Opinion in Rheumatology, 2017, 29, 369-373. | 2.0 | 31 |
| 89 | Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Seminars in Arthritis and Rheumatism, 2017, 47, 183-192. | 1.6 | 63 |
| 90 | MCPIP1/Regnase-1 Restricts IL-17Aâ€“ and IL-17Câ€“Dependent Skin Inflammation. Journal of Immunology, 2017, 198, 767-775. | 0.4 | 65 |
| 91 | Therapeutic Applications: Strategies and Molecules Targeting the IL-17/Th17 Pathway. , 2017, , 55-99. | | 0 |
| 92 | IL-17, now an important target for treatment in arthritis. Joint Bone Spine, 2017, 84, 247-249. | 0.8 | 5 |
| 93 | Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. Journal of the American Academy of Dermatology, 2017, 76, 670-675. | 0.6 | 137 |
| 95 | Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery, 2017, 21, 2S-40S. | 0.6 | 9 |
| 96 | Patient Burden of Axial Spondyloarthritis. Journal of Clinical Rheumatology, 2017, 23, 383-391. | 0.5 | 85 |
| 97 | Pathogenetic Concepts of Joint Diseases. Learning Materials in Biosciences, 2017, , 173-187. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 98 | Pathological and therapeutic roles of innate lymphoid cells in diverse diseases. Archives of Pharmacal Research, 2017, 40, 1249-1264. | 2.7 | 3 |
| 99 | Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology, 2017, 56, 1993-2003. | 0.9 | 121 |
| 100 | Tumor necrosis factor-Î± (TNFÎ±) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 197-210. | 1.2 | 13 |
| 102 | A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatology and Therapy, 2017, 4, 233-246. | 1.1 | 20 |
| 103 | Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Review of Clinical Pharmacology, 2017, 10, 1363-1374. | 1.3 | 18 |
| 104 | Inhibition of ILâ€17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clinical and Translational Immunology, 2017, 6, e152. | 1.7 | 67 |
| 105 | Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. Journal of Pediatrics, 2017, 189, 31-39. | 0.9 | 3 |
| 106 | Endothelial cells: From innocent bystanders to active participants in immune responses. Autoimmunity Reviews, 2017, 16, 951-962. | 2.5 | 109 |
| 108 | Mechanism of New Bone Formation in Axial Spondyloarthritis. Current Rheumatology Reports, 2017, 19, 55. | 2.1 | 58 |
| 109 | Les enthÃ©sites. Revue Du Rhumatisme (Edition Francaise), 2017, 84, A21-A28. | 0.0 | 0 |
| 110 | Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open, 2017, 3, e000524. | 1.8 | 35 |
| 111 | Teriparatide and vertebral fracture healing in Ankylosing Spondylitis. Trauma Case Reports, 2017, 12, 34-39. | 0.2 | 2 |
| 112 | Secukinumab in Active Rheumatoid Arthritis after Anti-TNFÎ± Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. Rheumatology and Therapy, 2017, 4, 475-488. | 1.1 | 25 |
| 113 | Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nature Communications, 2017, 8, 1510. | 5.8 | 118 |
| 116 | Etanercept for treating axial spondyloarthritis. Expert Opinion on Biological Therapy, 2017, 17, 1173-1181. | 1.4 | 15 |
| 118 | Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Clinical Rheumatology, 2017, 36, 1569-1577. | 1.0 | 17 |
| 119 | Treatment of psoriatic arthritis with traditional DMARDâ€™s and novel therapies: approaches and recommendations. Expert Review of Clinical Immunology, 2017, 13, 319-331. | 1.3 | 7 |
| 120 | Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors. Clinical Rheumatology, 2017, 36, 143-154. | 1.0 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 121 | Biologic Therapy for HLA-B27-associated Ocular Disorders. Ocular Immunology and Inflammation, 2017, 25, 169-178. | 1.0 | 17 |
| 122 | Secukinumab for Longâ€Term Treatment of Psoriatic Arthritis: A Twoâ€Year Followup From a Phase III, Randomized, Doubleâ€Blind Placeboâ€Controlled Study. Arthritis Care and Research, 2017, 69, 347-355. | 1.5 | 72 |
| 123 | A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers. Nucleic Acid Therapeutics, 2017, 27, 36-44. | 2.0 | 43 |
| 125 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Âyear: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2017, 76, 60-69.e9. | 0.6 | 258 |
| 126 | Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open, 2017, 3, e000592. | 1.8 | 68 |
| 127 | Rheumatoid Arthritis and Other Inflammatory Articular Diseases. , 2017, , 1105-1140. | | 1 |
| 128 | Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders. Molecules, 2017, 22, 134. | 1.7 | 180 |
| 129 | T Helper 17 Cells in Primary SjÃ¶grenâ€™s Syndrome. Journal of Clinical Medicine, 2017, 6, 65. | 1.0 | 36 |
| 130 | IL-23 and Th17 Disease in Inflammatory Arthritis. Journal of Clinical Medicine, 2017, 6, 81. | 1.0 | 51 |
| 131 | Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/HuÎ²2m Transgenic Rats. Frontiers in Immunology, 2017, 8, 920. | 2.2 | 29 |
| 132 | Anti-IL17A in Axial Spondyloarthritisâ€”Where Are We At?. Frontiers in Medicine, 2017, 4, 1. | 1.2 | 60 |
| 133 | Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators of Inflammation, 2017, 2017, 1-15. | 1.4 | 93 |
| 134 | Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Research and Therapy, 2017, 19, 285. | 1.6 | 161 |
| 135 | Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. Arthritis Research and Therapy, 2017, 19, 286. | 1.6 | 18 |
| 136 | Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study. BMJ Open, 2017, 7, e016548. | 0.8 | 0 |
| 137 | The immune dysfunction in ankylosing spondylitis patients. BioScience Trends, 2017, 11, 69-76. | 1.1 | 21 |
| 139 | Uveitis in the Spondyloarthopathies. Best Practice and Research in Clinical Rheumatology, 2017, 31, 846-862. | 1.4 | 57 |
| 140 | Th17 cell responses in spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 777-796. | 1.4 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 141 | Vitamin D Deficiency in Axial Spondyloarthritis is Associated With Higher Disease Activity. Archives of Rheumatology, 2017, 32, 209-215. | 0.3 | 14 |
| 142 | Comparative Efficacy and Safety of Secukinumab and Adalimumab in Patients with Active Ankylosing Spondylitis: A Bayesian Network Meta-analysis of Randomized Controlled Trials. Journal of Rheumatic Diseases, 2017, 24, 211. | 0.4 | 16 |
| 143 | Secukinumab after anti-tumour necrosis factor-Î± therapy: a phase III study in active rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2018, 47, 276-281. | 0.6 | 30 |
| 144 | Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton. Calcified Tissue International, 2018, 102, 607-618. | 1.5 | 44 |
| 145 | Emerging drugs for the treatment of axial spondyloarthritis. Expert Opinion on Emerging Drugs, 2018, 23, 83-96. | 1.0 | 9 |
| 146 | Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 153-157. | 1.0 | 12 |
| 147 | New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Therapeutic Advances in Chronic Disease, 2018, 9, 77-87. | 1.1 | 40 |
| 148 | 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine, 2018, 85, 275-284. | 0.8 | 80 |
| 150 | Safety of treatment options for spondyloarthritis: a narrative review. Expert Opinion on Drug Safety, 2018, 17, 475-486. | 1.0 | 20 |
| 151 | Biologics for treating axial spondyloarthritis. Expert Opinion on Biological Therapy, 2018, 18, 641-652. | 1.4 | 20 |
| 152 | Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. Clinical Rheumatology, 2018, 37, 1581-1588. | 1.0 | 38 |
| 153 | Current and future perspectives in the management of juvenile idiopathic arthritis. The Lancet Child and Adolescent Health, 2018, 2, 360-370. | 2.7 | 39 |
| 154 | Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis. Advances in Therapy, 2018, 35, 424-437. | 1.3 | 11 |
| 156 | Shifting the focus â€“ the primary role of <scp>IL</scp>â€23 in psoriasis and other inflammatory disorders. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1111-1119. | 1.3 | 80 |
| 157 | The Role of Autophagy in the Degradation of Misfolded <scp>HLA</scp>â€“B27 Heavy Chains. Arthritis and Rheumatology, 2018, 70, 746-755. | 2.9 | 28 |
| 158 | The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. Immunology Letters, 2018, 196, 52-62. | 1.1 | 59 |
| 159 | Th17â€¯cells, Î³Î´ T cells and their interplay in EAE and multiple sclerosis. Journal of Autoimmunity, 2018, 87, 97-108. | 3.0 | 94 |
| 160 | From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications. Expert Review of Clinical Immunology, 2018, 14, 207-213. | 1.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 161 | Th17 plasticity and its relevance to inflammatory bowel disease. Journal of Autoimmunity, 2018, 87, 38-49. | 3.0 | 214 |
| 162 | Autoimmunity and primary immunodeficiency: two sides of the same coin?. Nature Reviews Rheumatology, 2018, 14, 7-18. | 3.5 | 103 |
| 163 | Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 2018, 78, 383-394. | 0.6 | 69 |
| 164 | Genetics of immune-mediated inflammatory diseases. Clinical and Experimental Immunology, 2018, 193, 3-12. | 1.1 | 66 |
| 165 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. Drug Safety, 2018, 41, 473-488. | 1.4 | 30 |
| 166 | Current and Emerging Treatments for Psoriatic Arthritis. , 2018, , 175-185. | | 1 |
| 167 | Production of IL-17 by MAIT Cells Is Increased in Multiple Sclerosis and Is Associated with IL-7 Receptor Expression. Journal of Immunology, 2018, 200, 974-982. | 0.4 | 58 |
| 168 | Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. Arthritis Research and Therapy, 2018, 20, 61. | 1.6 | 32 |
| 169 | Novel Therapeutic Targets in Axial Spondyloarthritis. Current Treatment Options in Rheumatology, 2018, 4, 174-182. | 0.6 | 8 |
| 170 | Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis. Current Opinion in Rheumatology, 2018, 30, 340-346. | 2.0 | 4 |
| 171 | Secukinumab shows high efficacy irrespective ofHLA-Cw6status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. British Journal of Dermatology, 2018, 179, 1072-1080. | 1.4 | 44 |
| 172 | Quantifying the genetic risk for the development of axial spondyloarthropathy: could this become a diagnostic tool?. Current Opinion in Rheumatology, 2018, 30, 319-323. | 2.0 | 2 |
| 173 | Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 818-826. | 1.0 | 34 |
| 174 | Cytokines in uveitis. Current Opinion in Ophthalmology, 2018, 29, 267-274. | 1.3 | 79 |
| 175 | Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028522. | 2.3 | 226 |
| 176 | Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. British Journal of Dermatology, 2018, 179, 182-185. | 1.4 | 63 |
| 177 | What is the best treatment target in axial spondyloarthritis: tumour necrosis factor Î±, interleukin 17, or both?. Rheumatology, 2018, 57, 1145-1150. | 0.9 | 25 |
| 178 | Bone Disease in Axial Spondyloarthritis. Calcified Tissue International, 2018, 102, 547-558. | 1.5 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 179 | Antiâ€Lâ€23 and Antiâ€Lâ€17 Biologic Agents for the Treatment of Immuneâ€Mediated Inflammatory Conditions. Clinical Pharmacology and Therapeutics, 2018, 103, 88-101. | 2.3 | 55 |
| 180 | Review: Genetics and the Classification of Arthritis in Adults and Children. Arthritis and Rheumatology, 2018, 70, 7-17. | 2.9 | 100 |
| 181 | Recomendaciones de la Sociedad EspaÃ±ola de ReumatologÃa sobre el tratamiento y uso de terapias sistÃ©micas biolÃ³gicas y no biolÃ³gicas en artritis psoriÃ¡sica. ReumatologÃa ClÃnica, 2018, 14, 254-268. | 0.2 | 32 |
| 182 | Recomendaciones de la Sociedad EspaÃ±ola de ReumatologÃa sobre el uso de terapias biolÃ³gicas en espondiloartritis axial. ReumatologÃa ClÃnica, 2018, 14, 320-333. | 0.2 | 24 |
| 183 | Safety of biologics in psoriasis. Journal of Dermatology, 2018, 45, 279-286. | 0.6 | 94 |
| 184 | Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis. Expert Opinion on Biological Therapy, 2018, 18, 101-107. | 1.4 | 27 |
| 185 | Interleukinâ€17 family cytokines in protective immunity against infections: role of hematopoietic cellâ€derived and nonâ€hematopoietic cellâ€derived interleukinâ€17s. Microbiology and Immunology, 2018, 62, 1-13. | 0.7 | 84 |
| 186 | Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. Journal of Comparative Effectiveness Research, 2018, 7, 369-380. | 0.6 | 28 |
| 188 | Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. Rheumatology, 2018, 57, 419-428. | 0.9 | 11 |
| 189 | Unmet Needs in Axial Spondyloarthritis. Clinical Reviews in Allergy and Immunology, 2018, 55, 332-339. | 2.9 | 22 |
| 190 | Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. BMJ Open, 2018, 8, e018166. | 0.8 | 15 |
| 191 | Emerging treatment options for spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 472-484. | 1.4 | 15 |
| 192 | Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open, 2018, 4, e000749. | 1.8 | 30 |
| 193 | An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 453-471. | 1.4 | 16 |
| 194 | Mechanisms and functions of IL-17 signaling in renal autoimmune diseases. Molecular Immunology, 2018, 104, 90-99. | 1.0 | 16 |
| 195 | Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis. ReumatologÃa ClÃnica (English Edition), 2018, 14, 320-333. | 0.2 | 3 |
| 196 | Aberrant expression of interleukin-23-regulated miRNAs in T cells from patients with ankylosing spondylitis. Arthritis Research and Therapy, 2018, 20, 259. | 1.6 | 15 |
| 197 | Axial spondyloarthritis including ankylosing spondylitis. Rheumatology, 2018, 57, vi1-vi3. | 0.9 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 198 | Therapies in ankylosing spondylitisâ€"from clinical trials to clinical practice. Rheumatology, 2018, 57, vi23-vi28. | 0.9 | 27 |
| 199 | Optimizing outcomes for ankylosing spondylitis and axial spondyloarthritis patients: a holistic approach to care. Rheumatology, 2018, 57, vi29-vi34. | 0.9 | 25 |
| 200 | The current standard of care and the unmet needs for axial spondyloarthritis. Rheumatology, 2018, 57, vi10-vi17. | 0.9 | 19 |
| 201 | Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology, 2018, 57, vi4-vi9. | 0.9 | 100 |
| 202 | MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?. RMD Open, 2018, 4, e000821. | 1.8 | 19 |
| 203 | Genetics and Functional Genomics of Spondyloarthritis. Frontiers in Immunology, 2018, 9, 2933. | 2.2 | 47 |
| 204 | The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science. Frontiers in Immunology, 2018, 9, 2668. | 2.2 | 73 |
| 205 | IL-17A contributes to perioperative neurocognitive disorders through blood-brain barrier disruption in aged mice. Journal of Neuroinflammation, 2018, 15, 332. | 3.1 | 72 |
| 206 | Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Research and Therapy, 2018, 20, 272. | 1.6 | 30 |
| 207 | Turkish League Against Rheumatism Consensus Report: Recommendations For Management of Axial Spondyloarthritis. Archives of Rheumatology, 2018, 33, 1-16. | 0.3 | 4 |
| 208 | Effects of the IL-23â€"IL-17 pathway onÂbone in spondyloarthritis. Nature Reviews Rheumatology, 2018, 14, 631-640. | 3.5 | 154 |
| 209 | Identification of key genes in Ankylosing spondylitis. Immunology Letters, 2018, 204, 60-66. | 1.1 | 0 |
| 210 | Recommendations of the Spanish Society of Rheumatology on Treatment and Use of Systemic Biological and Non-biological Therapies in Psoriatic Arthritis. ReumatologÃa ClÃnica (English Edition), 2018, 14, 254-268. | 0.2 | 6 |
| 211 | Learning from the youngsters: ixekizumab in active ankylosing spondylitis. Lancet, The, 2018, 392, 2415-2416. | 6.3 | 3 |
| 212 | Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases. Scientific Reports, 2018, 8, 15645. | 1.6 | 27 |
| 213 | Epidemiology and Immunopathogenesis of Psoriasis and Its Comorbidities. Current Dermatology Reports, 2018, 7, 321-329. | 1.1 | 0 |
| 214 | The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmunity Reviews, 2018, 17, 1251-1258. | 2.5 | 2 |
| 215 | Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opinion on Investigational Drugs, 2018, 27, 917-930. | 1.9 | 133 |

| # | Article | IF | Citations |
|---|---|---|---|
| 216 | Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). Dermatology and Therapy, 2018, 8, 571-579. | 1.4 | 59 |
| 217 | Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet, The, 2018, 392, 2441-2451. | 6.3 | 251 |
| 218 | The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 169-180. | 1.2 | 16 |
| 219 | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 477-491. | 0.7 | 9 |
| 220 | The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling. Frontiers in Immunology, 2018, 9, 1550. | 2.2 | 65 |
| 221 | Beyond the TNF-Î± Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology. Drugs, 2018, 78, 1397-1418. | 4.9 | 16 |
| 222 | Disorders of the Chest Wall. Clinics in Chest Medicine, 2018, 39, 361-375. | 0.8 | 15 |
| 223 | Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 129-139. | 1.2 | 86 |
| 224 | A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis. Case Reports in Gastrointestinal Medicine, 2018, 2018, 1-4. | 0.2 | 28 |
| 225 | Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2018, 45, 1389-1396. | 1.0 | 100 |
| 226 | Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis. Ophthalmology, 2018, 125, 1977-1983. | 2.5 | 58 |
| 227 | Influence of TNF and IL17 Gene Polymorphisms on the Spondyloarthritis Immunopathogenesis, Regardless of HLA-B27, in a Brazilian Population. Mediators of Inflammation, 2018, 2018, 1-7. | 1.4 | 19 |
| 228 | Individual Drugs in Rheumatology and theÂRisk of Infection. , 2018, , 445-464. | | 0 |
| 229 | Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. Mediators of Inflammation, 2018, 2018, 1-8. | 1.4 | 30 |
| 230 | Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions. Archives of Rheumatology, 2018, 33, 108-127. | 0.3 | 5 |
| 231 | Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis. Frontiers in Immunology, 2018, 9, 1610. | 2.2 | 59 |
| 232 | Molecularly endowed hydrogel with anin silico-assisted screened peptide for highly sensitive small molecule harvesting. Chemical Communications, 2018, 54, 10088-10091. | 2.2 | 18 |
| 233 | Relapsing Polychondritis following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature. Case Reports in Rheumatology, 2018, 2018, 1-4. | 0.2 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 234 | Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing Î³Î´ T Cells, Î±Î² T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis. Frontiers in Immunology, 2018, 9, 885. | 2.2 | 26 |
| 235 | It Takes â€œGutsâ€•to Cause Joint Inflammation: Role of Innate-Like T Cells. Frontiers in Immunology, 2018, 9, 1489. | 2.2 | 31 |
| 236 | IL-17 in the immunopathogenesis of spondyloarthritis. Nature Reviews Rheumatology, 2018, 14, 453-466. | 3.5 | 102 |
| 237 | Inflammatory Profiles of the Interleukin Family and Network in Cerebral Hemorrhage. Cellular and Molecular Neurobiology, 2018, 38, 1321-1333. | 1.7 | 29 |
| 238 | Personalized Axial Spondyloarthritis Care. Current Treatment Options in Rheumatology, 2018, 4, 158-173. | 0.6 | 1 |
| 239 | Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nature Reviews Rheumatology, 2018, 14, 363-371. | 3.5 | 149 |
| 240 | Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab. Journal of Crohn's and Colitis, 2018, 12, 1131-1133. | 0.6 | 41 |
| 241 | The Seronegative Spondyloarthropathies. Primary Care - Clinics in Office Practice, 2018, 45, 271-287. | 0.7 | 31 |
| 242 | Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Review of Clinical Immunology, 2018, 14, 751-759. | 1.3 | 14 |
| 243 | NLRP3 inflammasomes and NLRP3 inflammasome-derived proinflammatory cytokines in peripheral blood mononuclear cells of patients with ankylosing spondylitis. Clinica Chimica Acta, 2018, 486, 269-274. | 0.5 | 28 |
| 244 | Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open, 2018, 4, e000723. | 1.8 | 56 |
| 245 | Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the Rheumatic Diseases, 2018, 77, 1295-1302. | 0.5 | 275 |
| 246 | Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatology International, 2018, 38, 2121-2131. | 1.5 | 30 |
| 247 | Efficacy and Safety of Secukinumab 150Âmg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study. Rheumatology and Therapy, 2018, 5, 447-462. | 1.1 | 73 |
| 248 | Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. Journal of Medicinal Chemistry, 2018, 61, 10415-10439. | 2.9 | 26 |
| 249 | Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. Pharmacoeconomics, 2018, 36, 1015-1027. | 1.7 | 15 |
| 250 | Disease Modification in Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2018, 4, 197-213. | 0.6 | 0 |
| 251 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunology, 2018, 11, 1558-1570. | 2.7 | 80 |

| # | Article | IF | Citations |
|---|---|---|---|
| 252 | Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics. Current Opinion in Rheumatology, 2018, 30, 526-532. | 2.0 | 27 |
| 253 | Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohnâ€™s Disease: Analyses of Phase I and II Trials. Clinical Pharmacokinetics, 2019, 58, 375-387. | 1.6 | 25 |
| 254 | Spondyloarthritis. , 2019, , 769-787. | | 5 |
| 255 | Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2Âyears of treatment: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2019, 81, 1405-1409. | 0.6 | 14 |
| 256 | Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Research, 2019, 7, 22. | 5.4 | 229 |
| 257 | 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care and Research, 2019, 71, 1285-1299. | 1.5 | 274 |
| 258 | 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 1599-1613. | 2.9 | 401 |
| 259 | Systematic review with metaâ€analysis: risk of new onset IBD with the use of antiâ€interleukinâ€17 agents. Alimentary Pharmacology and Therapeutics, 2019, 50, 373-385. | 1.9 | 44 |
| 260 | Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1510-1519. | 1.1 | 57 |
| 261 | The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Annals of the Rheumatic Diseases, 2019, 78, 1167-1178. | 0.5 | 152 |
| 262 | IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. Journal of Allergy and Clinical Immunology, 2019, 144, 750-763. | 1.5 | 104 |
| 263 | Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study. Journal of Dermatology, 2019, 46, 752-758. | 0.6 | 12 |
| 264 | Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatology and Therapy, 2019, 6, 435-450. | 1.1 | 16 |
| 265 | The IL-23/IL-17 pathway in human chronic inflammatory diseases â€“ new insight from genetics and targeted therapies. Microbes and Infection, 2019, 21, 246-253. | 1.0 | 14 |
| 266 | A Hierarchical Peptideâ€“Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Proteinâ€“Protein Interaction. Nano Letters, 2019, 19, 7918-7926. | 4.5 | 22 |
| 267 | Awareness of axial spondyloarthritis among chiropractors and osteopaths: findings from a UK Web-based survey. Rheumatology Advances in Practice, 2019, 3, rkz034. | 0.3 | 12 |
| 268 | Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors. JAMA Network Open, 2019, 2, e1913102. | 2.8 | 25 |
| 269 | Therapeutic Vaccines as Novel Immunotherapy. , 2019, , . | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 270 | Treat to Target in Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2019, 45, 519-535. | 0.8 | 8 |
| 271 | A novel mouse model for septic arthritis induced by Pseudomonas aeruginosa. Scientific Reports, 2019, 9, 16868. | 1.6 | 11 |
| 272 | Antiâ€tumor necrosis factor treatment increases both the Th17 and Th22 T helper subsets in spondyloarthritis. Apmis, 2019, 127, 789-796. | 0.9 | 3 |
| 273 | Precision medicine in psoriatic arthritis: how should we select targeted therapies?. Lancet Rheumatology, The, 2019, 1, e66-e73. | 2.2 | 4 |
| 274 | Serological Biomarkers in Early Axial Spondyloarthritis During 24-Months Follow Up (Italian Arm of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 1.2 | 9 |
| 275 | TCR repertoire and CDR3 motif analyses depict the role of Î±Î² T cells in Ankylosing spondylitis. EBioMedicine, 2019, 47, 414-426. | 2.7 | 32 |
| 276 | Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension. Frontiers in Pharmacology, 2019, 10, 1015. | 1.6 | 36 |
| 277 | Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006â€“2016. BMC Rheumatology, 2019, 3, 39. | 0.6 | 31 |
| 278 | Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacological Research, 2019, 149, 104473. | 3.1 | 16 |
| 279 | Evidence that tissue resident human enthesis Î³Î´T-cells can produce IL-17A independently of IL-23R transcript expression. Annals of the Rheumatic Diseases, 2019, 78, 1559-1565. | 0.5 | 109 |
| 280 | The IL-23â€“IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nature Reviews Rheumatology, 2019, 15, 747-757. | 3.5 | 78 |
| 281 | RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitisâ€"Novel Targets for Therapy?. Frontiers in Immunology, 2018, 9, 3132. | 2.2 | 21 |
| 282 | Pharmacological management of axial spondyloarthritis in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1483-1491. | 0.9 | 9 |
| 283 | A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective. International Journal of Rheumatic Diseases, 2019, 22, 1630-1637. | 0.9 | 5 |
| 284 | Secukinumab induced BehÃ§etâ€™s syndrome: a report of two cases. Oxford Medical Case Reports, 2019, 2019, omz041. | 0.2 | 26 |
| 285 | Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 135. | 1.6 | 27 |
| 286 | Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis. Current Rheumatology Reports, 2019, 21, 35. | 2.1 | 11 |
| 287 | Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. BioDrugs, 2019, 33, 391-399. | 2.2 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 288 | Spinal radiographic progression over 2Âyears in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Research and Therapy, 2019, 21, 142. | 1.6 | 31 |
| 289 | Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Current Medical Research and Opinion, 2019, 35, 1751-1759. | 0.9 | 14 |
| 290 | Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2. ACS Medicinal Chemistry Letters, 2019, 10, 972-977. | 1.3 | 16 |
| 291 | A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab. Drugs - Real World Outcomes, 2019, 6, 83-91. | 0.7 | 5 |
| 292 | HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications. Nature Reviews Rheumatology, 2019, 15, 364-381. | 3.5 | 47 |
| 293 | Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials. Clinical Rheumatology, 2019, 38, 2765-2776. | 1.0 | 15 |
| 294 | The IL-23/IL-17 pathway in human chronic inflammatory diseasesâ€"new insight from genetics and targeted therapies. Genes and Immunity, 2019, 20, 415-425. | 2.2 | 38 |
| 295 | Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research and Therapy, 2019, 21, 111. | 1.6 | 215 |
| 296 | The IL-17 Family of Cytokines in Health and Disease. Immunity, 2019, 50, 892-906. | 6.6 | 773 |
| 297 | Bone Pathophysiology in Axial Spondyloarthritis. , 2019, , 111-120. | | 0 |
| 298 | Pharmacologic Nonbiologic Treatment of Axial Spondyloarthritis. , 2019, , 217-226. | | 0 |
| 299 | Biologic Treatment of Axial Spondyloarthritis. , 2019, , 227-242. | | 2 |
| 300 | Treatment Guidelines for Axial Spondyloarthritis. , 2019, , 243-258. | | 0 |
| 301 | DNA methylation and transcriptome signature of the IL12B gene in ankylosing spondylitis. International Immunopharmacology, 2019, 71, 109-114. | 1.7 | 16 |
| 302 | Persistence, Discontinuation, and Switching Patterns of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients in the United States. Rheumatology and Therapy, 2019, 6, 207-215. | 1.1 | 17 |
| 303 | Interleukin-17A blockade reduces albuminuria andÂkidney injury in an accelerated model of diabetic nephropathy. Kidney International, 2019, 95, 1418-1432. | 2.6 | 78 |
| 304 | 2018 APLAR axial spondyloarthritis treatment recommendations. International Journal of Rheumatic Diseases, 2019, 22, 340-356. | 0.9 | 59 |
| 305 | Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Annals of the Rheumatic Diseases, 2019, 78, 473-479. | 0.5 | 143 |

| # | Article | IF | Citations |
|---|---|---|---|
| 306 | Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center. Rheumatology International, 2019, 39, 663-668. | 1.5 | 1 |
| 307 | The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. Expert Review of Clinical Immunology, 2019, 15, 629-637. | 1.3 | 39 |
| 308 | IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opinion on Biological Therapy, 2019, 19, 631-641. | 1.4 | 20 |
| 309 | Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. Frontiers in Immunology, 2019, 10, 382. | 2.2 | 62 |
| 310 | Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. Rheumatology and Therapy, 2019, 6, 165-177. | 1.1 | 32 |
| 311 | Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nature Reviews Rheumatology, 2019, 15, 153-166. | 3.5 | 208 |
| 312 | Treating to Target(s) With Interleukin-17 Inhibitors. Journal of Cutaneous Medicine and Surgery, 2019, 23, 3S-34S. | 0.6 | 6 |
| 313 | Secukinumab: A Review in Ankylosing Spondylitis. Drugs, 2019, 79, 433-443. | 4.9 | 62 |
| 314 | Phenotypes in BehÃ§etâ€™s syndrome. Internal and Emergency Medicine, 2019, 14, 677-689. | 1.0 | 80 |
| 315 | FRI0405â€…AQUILA STUDY IN GERMANY â€“ REAL WORLD DATA ON SECUKINUMABâ€™S EFFECTIVENESS IN PSORIATIC ARTHRITIS PATIENTS â€“ RESULTS FROM AN INTERIM ANALYSIS. , 2019, , . | | 1 |
| 316 | SAT0315â€…STRUCTURAL DAMAGE PROGRESSION OVER 4 YEARS OF SECUKINUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: POST-HOC ANALYSIS OF MEASURE-1 TRIAL USING A LONGITUDINAL BAYESIAN MIXTURE MODEL. , 2019, , . | | 0 |
| 317 | Bone formation in axial spondyloarthritis: Is disease modification possible?. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101491. | 1.4 | 12 |
| 318 | Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open, 2019, 5, e001005. | 1.8 | 70 |
| 319 | JAK inhibitors: promising for a wider spectrum of autoimmune diseases?. Lancet, The, 2019, 394, 2047-2048. | 6.3 | 3 |
| 321 | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases. Frontiers in Pharmacology, 2019, 10, 1315. | 1.6 | 66 |
| 323 | Treatment of juvenile idiopathic arthritis: what's new?. Current Opinion in Rheumatology, 2019, 31, 428-435. | 2.0 | 18 |
| 324 | Biological Modifiers of Inflammatory Diseases. , 2019, , 1197-1210.e1. | | 1 |
| 325 | Efficacy of the anti-IL 17 secukinumab in refractory BehÃ§et's syndrome: A preliminary study. Journal of Autoimmunity, 2019, 97, 108-113. | 3.0 | 50 |

| # | Article | IF | Citations |
|---|---|---|---|
| 326 | A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis. Rheumatology and Therapy, 2019, 6, 5-21. | 1.1 | 7 |
| 327 | The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Review of Clinical Immunology, 2019, 15, 123-134. | 1.3 | 54 |
| 328 | Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology, 2019, 58, 859-868. | 0.9 | 108 |
| 329 | RORÎ³t inhibition selectively targets IL-17 producing iNKT and Î³Î´-T cells enriched in Spondyloarthritis patients. Nature Communications, 2019, 10, 9. | 5.8 | 255 |
| 330 | The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?. Journal of Clinical Pharmacology, 2019, 59, 445-462. | 1.0 | 22 |
| 331 | Ankylosing spondylitis and mesenchymal stromal/stem cell therapy: a new therapeutic approach. Biomedicine and Pharmacotherapy, 2019, 109, 1196-1205. | 2.5 | 31 |
| 332 | Modelâ€Based Metaâ€Analysis in Ankylosing Spondylitis: A Quantitative Comparison of Biologics and Small Targeted Molecules. Clinical Pharmacology and Therapeutics, 2019, 105, 1244-1255. | 2.3 | 5 |
| 333 | Association between IL23R and ERAP1 polymorphisms and sacroiliac or spinal MRI inflammation in spondyloarthritis: DESIR cohort data. Arthritis Research and Therapy, 2019, 21, 22. | 1.6 | 11 |
| 334 | Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. Drugs - Real World Outcomes, 2019, 6, 1-9. | 0.7 | 2 |
| 335 | Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, 941-953. | 1.8 | 27 |
| 336 | Protein inhibitor of activated STAT3 reduces peripheral arthritis and gut inflammation and regulates the Th17/Treg cell imbalance via STAT3 signaling in a mouse model of spondyloarthritis. Journal of Translational Medicine, 2019, 17, 18. | 1.8 | 20 |
| 337 | Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteenâ€Week ResultsÂFrom a Phase <scp>III</scp> Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2019, 71, 599-611. | 2.9 | 142 |
| 338 | Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?. Annals of the Rheumatic Diseases, 2019, 78, 1015-1018. | 0.5 | 77 |
| 339 | Innate Lymphoid Cells and T Cells Contribute to the Interleukinâ€17A Signature Detected in the Synovial Fluid of Patients With Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2019, 71, 460-467. | 2.9 | 19 |
| 340 | Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. Journal of Medical Economics, 2019, 22, 45-52. | 1.0 | 10 |
| 341 | Interleukinâ€17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 612-625. | 2.9 | 87 |
| 342 | Use of synthetic and biologic DMARDs during pregnancy. Expert Review of Clinical Immunology, 2019, 15, 27-39. | 1.3 | 7 |
| 343 | Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content. Rheumatology, 2019, 58, 617-627. | 0.9 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 344 | The ties that bind: skin, gut and spondyloarthritis. Current Opinion in Rheumatology, 2019, 31, 62-69. | 2.0 | 36 |
| 345 | Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy, 2019, 19, 55-64. | 1.4 | 34 |
| 346 | Expansion of Interleukinâ€22â€“ and Granulocyteâ€“Macrophage Colonyâ€Stimulating Factorâ€“Expressing, but Not Interleukinâ€17Aâ€“Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 392-402. | 2.9 | 30 |
| 347 | Biologics in SAPHO syndrome: A systematic review. Seminars in Arthritis and Rheumatism, 2019, 48, 618-625. | 1.6 | 74 |
| 348 | Associations between interleukin-23R polymorphisms and ankylosing spondylitis susceptibility: an updated meta-analysis. Zeitschrift Fur Rheumatologie, 2019, 78, 272-280. | 0.5 | 9 |
| 349 | Associated factors with adherence to standard exercise therapy and health-related quality of life in Chinese patients with ankylosing spondylitis. Modern Rheumatology, 2020, 30, 149-154. | 0.9 | 10 |
| 350 | Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). Modern Rheumatology, 2020, 30, 132-140. | 0.9 | 25 |
| 351 | Secukinumab dosing optimization in patients with moderateâ€toâ€severe plaque psoriasis: results from the randomized, openâ€label <scp>OPTIMISE</scp> study. British Journal of Dermatology, 2020, 182, 304-315. | 1.4 | 33 |
| 352 | Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. Journal of Rheumatology, 2020, 47, 539-547. | 1.0 | 16 |
| 353 | Psoriatic arthritis for dermatologists. Journal of Dermatological Treatment, 2020, 31, 662-679. | 1.1 | 52 |
| 355 | Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Current Medical Research and Opinion, 2020, 36, 7-8. | 0.9 | 5 |
| 356 | Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. Journal of Rheumatology, 2020, 47, 854-864. | 1.0 | 10 |
| 357 | Treatment of Autoimmune Disease: Established Therapies. , 2020, , 1415-1435. | | 0 |
| 358 | New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. Scandinavian Journal of Rheumatology, 2020, 49, 75-76. | 0.6 | 9 |
| 360 | The role of interleukin-17 in tumor development and progression. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 135 |
| 361 | Polyfunctional, Proinflammatory, Tissueâ€Resident Memory Phenotype and Function of Synovial Interleukinâ€17A+<scp>CD</scp>8+ T Cells in Psoriatic Arthritis. Arthritis and Rheumatology, 2020, 72, 435-447. | 2.9 | 77 |
| 363 | Beyond Randomized Clinical Trials: Use of External Controls. Clinical Pharmacology and Therapeutics, 2020, 107, 806-816. | 2.3 | 65 |
| 364 | Discovery of Potential Serum Protein Biomarkers in Ankylosing Spondylitis Using Tandem Mass Tag-Based Quantitative Proteomics. Journal of Proteome Research, 2020, 19, 864-872. | 1.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 365 | From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. Lancet Rheumatology, The, 2020, 2, e50-e62. | 2.2 | 17 |
| 366 | mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo. Frontiers in Immunology, 2019, 10, 2344. | 2.2 | 23 |
| 367 | Interleukin-17 cytokines: Effectors and targets in psoriasisâ€"A breakthrough in understanding and treatment. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 54 |
| 368 | Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 55 |
| 369 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nature Reviews Rheumatology, 2020, 16, 32-52. | 3.5 | 68 |
| 371 | Update on recommendations for eligibility of government subsidization of biologic diseaseâ€modifying antirheumatic drugs for the treatment of axial spondyloarthritis in Singapore. International Journal of Rheumatic Diseases, 2020, 23, 165-173. | 0.9 | 3 |
| 372 | Longâ€term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1161-1173. | 1.3 | 32 |
| 373 | Inhibition of interleukin-17 in axial spondyloarthritis spectrum. Lancet, The, 2020, 395, 6-8. | 6.3 | 2 |
| 374 | Diffuse Idiopathic Skeletal Hyperostosis, Associated Morbidity, and Healthcare Utilization. Journal of Clinical Rheumatology, 2020, 26, 104-108. | 0.5 | 3 |
| 375 | Severe colitis complicating secukinumab (Cosentyx Â® ) therapy. Clinical and Experimental Dermatology, 2020, 45, 344-345. | 0.6 | 6 |
| 376 | LncRNA MEG3 inhibits the inflammatory response of ankylosing spondylitis by targeting miR-146a. Molecular and Cellular Biochemistry, 2020, 466, 17-24. | 1.4 | 37 |
| 377 | Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate. BMJ Open, 2020, 10, e039059. | 0.8 | 7 |
| 378 | Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1219-1231. | 0.5 | 3 |
| 379 | 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatology, The, 2020, 2, e339-e346. | 2.2 | 19 |
| 380 | The association between Candida infection and ankylosing spondylitis: a population-based matched cohort study. Current Medical Research and Opinion, 2020, 36, 2063-2069. | 0.9 | 7 |
| 381 | Punicalagin Exerts Protective Effects against Ankylosing Spondylitis by Regulating NF-ÎB-TH17/JAK2/STAT3 Signaling and Oxidative Stress. BioMed Research International, 2020, 2020, 1-12. | 0.9 | 18 |
| 382 | Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. Journal of Dermatological Treatment, 2022, 33, 1482-1490. | 1.1 | 6 |
| 383 | Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. Rheumatology, 2020, 59, 3657-3665. | 0.9 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 384 | Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2020, 12, 566922. | 1.7 | 79 |
| 385 | Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2020, 39, 160-166. | 0.8 | 5 |
| 386 | Effects of exercise programmes on pain, disease activity and function in ankylosing spondylitis: A metaâ€analysis of randomized controlled trials. European Journal of Clinical Investigation, 2020, 50, e13352. | 1.7 | 10 |
| 387 | Treatment of Axial Spondyloarthritis: What Does the Future Hold?. Current Rheumatology Reports, 2020, 22, 47. | 2.1 | 20 |
| 388 | Paradoxical gastrointestinal effects of interleukin-17 blockers. Annals of the Rheumatic Diseases, 2020, 79, 1132-1138. | 0.5 | 140 |
| 389 | Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology, 2020, 59, 3158-3171. | 0.9 | 10 |
| 390 | GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis. Frontiers in Immunology, 2020, 11, 1520. | 2.2 | 16 |
| 391 | Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs. Mediators of Inflammation, 2020, 2020, 1-12. | 1.4 | 4 |
| 392 | Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1. Frontiers in Immunology, 2020, 11, 561748. | 2.2 | 4 |
| 393 | <scp>Oneâ€Year</scp> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care and Research, 2022, 74, 748-758. | 1.5 | 15 |
| 395 | Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <scp>Longâ€Term</scp> Results of Two Phase <scp>III</scp> Randomized Controlled Trials. Arthritis Care and Research, 2022, 74, 759-767. | 1.5 | 10 |
| 396 | <p>Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives</p>. Open Access Rheumatology: Research and Reviews, 2020, Volume 12, 277-292. | 0.8 | 4 |
| 397 | Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab. International Journal of Rheumatic Diseases, 2020, 23, 1175-1183. | 0.9 | 3 |
| 398 | New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology, 2020, 161, 94-102. | 2.0 | 55 |
| 399 | Ixekizumab for the treatment of ankylosing spondylitis. Expert Review of Clinical Immunology, 2020, 16, 745-750. | 1.3 | 9 |
| 400 | Secukinumab-induced ulcerative colitis: Opening Pandoraâ€™s box of immunity. GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 358-359. | 0.0 | 1 |
| 401 | Treatment strategies in axial spondyloarthritis: what, when and how?. Rheumatology, 2020, 59, iv79-iv89. | 0.9 | 41 |
| 402 | Measuring Outcomes in Axial Spondyloarthritis. Arthritis Care and Research, 2020, 72, 47-71. | 1.5 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 403 | Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5. Chinese Medical Journal, 2020, 133, 2521-2531. | 0.9 | 23 |
| 404 | Uveitis in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2095173. | 1.2 | 32 |
| 405 | Evaluating Inflammatory Versus Mechanical Back Pain in Individuals with Psoriatic Arthritis: A Review of the Literature. Rheumatology and Therapy, 2020, 7, 667-684. | 1.1 | 8 |
| 406 | Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open, 2020, 6, e001280. | 1.8 | 33 |
| 407 | Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?. Arthritis Research and Therapy, 2020, 22, 195. | 1.6 | 19 |
| 408 | Correspondence on â€˜Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohortâ€™ by Micheroliet al. Annals of the Rheumatic Diseases, 2022, 81, e226-e226. | 0.5 | 2 |
| 409 | Risk of tuberculosis in patients with spondyloarthritis: data from a centralized electronic database in Hong Kong. BMC Musculoskeletal Disorders, 2020, 21, 832. | 0.8 | 3 |
| 410 | Interleukin (IL)-12 and IL-18 Synergize to Promote MAIT Cell IL-17A and IL-17F Production Independently of IL-23 Signaling. Frontiers in Immunology, 2020, 11, 585134. | 2.2 | 41 |
| 411 | Positive association of Parkinsonâ€™s disease with ankylosing spondylitis: a nationwide population-based study. Journal of Translational Medicine, 2020, 18, 455. | 1.8 | 6 |
| 412 | Research hotspots and trends analysis of ankylosing spondylitis: a bibliometric and scientometric analysis from 2009 to 2018. Annals of Translational Medicine, 2020, 8, 1445-1445. | 0.7 | 12 |
| 413 | Th17 cell inhibition in a costimulation blockadeâ€based regimen for vascularized composite allotransplantation using a nonhuman primate model. Transplant International, 2020, 33, 1294-1301. | 0.8 | 10 |
| 414 | The Role of Th17/Treg Axis in the Traditional Chinese Medicine Intervention on Immune-Mediated Inflammatory Diseases: A Systematic Review. The American Journal of Chinese Medicine, 2020, 48, 535-558. | 1.5 | 9 |
| 415 | Defining theÂphenotype, pathogenesis and treatment of Crohnâ€™s diseaseÂassociated spondyloarthritis. Journal of Gastroenterology, 2020, 55, 667-678. | 2.3 | 9 |
| 416 | Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. Advances in Therapy, 2020, 37, 2865-2883. | 1.3 | 23 |
| 417 | Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis. Journal of Rheumatology, 2020, 47, 1606-1613. | 1.0 | 12 |
| 418 | Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Research and Therapy, 2020, 22, 111. | 1.6 | 45 |
| 419 | Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. Annals of the Rheumatic Diseases, 2020, 79, 1044-1054. | 0.5 | 56 |
| 420 | Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy. International Journal of Molecular Sciences, 2020, 21, 3798. | 1.8 | 142 |

| # | Article | IF | Citations |
|---|---|---|---|
| 421 | Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0233781. | 1.1 | 32 |
| 422 | Toxicological considerations in the treatment of axial spondylo-arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 663-672. | 1.5 | 1 |
| 423 | Pathogenesis of Axial Spondyloarthritis â€" Sources and Current State of Knowledge. Rheumatic Disease Clinics of North America, 2020, 46, 193-206. | 0.8 | 8 |
| 424 | Treat to Target in Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2020, 46, 343-356. | 0.8 | 10 |
| 425 | Fungal Infections Potentiated by Biologics. Infectious Disease Clinics of North America, 2020, 34, 389-411. | 1.9 | 14 |
| 426 | Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews, 2020, 33, . | 5.7 | 68 |
| 427 | IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology. Frontiers in Immunology, 2020, 11, 341. | 2.2 | 44 |
| 428 | Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study. BMC Rheumatology, 2020, 4, 19. | 0.6 | 9 |
| 429 | Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nature Reviews Rheumatology, 2020, 16, 282-292. | 3.5 | 76 |
| 430 | Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?. Biochemical Pharmacology, 2020, 177, 113894. | 2.0 | 8 |
| 431 | The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis â€" 2019. Advances in Rheumatology, 2020, 60, 19. | 0.8 | 16 |
| 432 | Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. International Journal of Molecular Sciences, 2020, 21, 1690. | 1.8 | 117 |
| 433 | Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. Modern Rheumatology Case Reports, 2020, 4, 176-180. | 0.3 | 1 |
| 434 | Dysregulation of the interleukin-17A pathway in endometrial tissue from women with unexplained infertility affects pregnancy outcome following assisted reproductive treatment. Human Reproduction, 2020, 35, 1875-1888. | 0.4 | 11 |
| 435 | An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093427. | 1.2 | 20 |
| 436 | Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases, 2020, 79, 1203-1209. | 0.5 | 37 |
| 437 | Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors. Experimental Biology and Medicine, 2020, 245, 1104-1114. | 1.1 | 13 |
| 438 | Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis. Zeitschrift Fur Rheumatologie, 2020, 80, 776-784. | 0.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 439 | Spondyloarthritis and sarcoidosis: Related or fake friends? A systematic literature review. Joint Bone Spine, 2020, 87, 579-587. | 0.8 | 8 |
| 440 | Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatology, 2020, 2, 449-456. | 0.9 | 22 |
| 442 | Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations. Digestion, 2020, 101, 83-97. | 1.2 | 19 |
| 443 | Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. OncoImmunology, 2020, 9, 1722023. | 2.1 | 37 |
| 444 | Innate lymphoid cells in inflammatory arthritis. Arthritis Research and Therapy, 2020, 22, 25. | 1.6 | 28 |
| 445 | Treat to target in axial spondyloarthritis: From its concept to its implementation. Journal of Autoimmunity, 2020, 110, 102398. | 3.0 | 25 |
| 446 | Interleukinâ€23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy. Immunological Reviews, 2020, 294, 27-47. | 2.8 | 60 |
| 447 | Interleukin-17 mRNA expression and serum levels in BehÃ§etâ€™s disease. Cytokine, 2020, 127, 154994. | 1.4 | 7 |
| 448 | Secukinumab can treat psoriasis induced by antiâ€TNFâ€alpha therapy in patients with ankylosing spondylitis: Case series. International Journal of Rheumatic Diseases, 2020, 23, 454-456. | 0.9 | 1 |
| 449 | Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). Clinical Drug Investigation, 2020, 40, 269-278. | 1.1 | 38 |
| 450 | Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3â€Year Results from the Phase 3 <scp>MEASURE</scp> 3 Study. ACR Open Rheumatology, 2020, 2, 119-127. | 0.9 | 30 |
| 451 | Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after antiâ€TNF failure. International Journal of Dermatology, 2020, 59, 733-735. | 0.5 | 17 |
| 452 | Incidence of Uveitis in Secukinumabâ€treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatology, 2020, 2, 294-299. | 0.9 | 33 |
| 453 | Selective targeting of PI3KÎ´ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. Journal of Autoimmunity, 2020, 111, 102435. | 3.0 | 25 |
| 454 | Drug-Induced Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1759-1779. | 2.4 | 20 |
| 455 | Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatology, 2020, 4, 16. | 0.6 | 12 |
| 457 | Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases, 2020, 79, 595-604. | 0.5 | 91 |
| 458 | Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States. Rheumatology and Therapy, 2020, 7, 415-423. | 1.1 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 459 | Novel whole-body magnetic resonance imaging response and remission criteria document diminished inflammation during golimumab treatment in axial spondyloarthritis. Rheumatology, 2020, 59, 3358-3368. | 0.9 | 13 |
| 460 | Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. Mediators of Inflammation, 2020, 2020, 1-5. | 1.4 | 20 |
| 461 | Circulating IL-17A Levels in Postmenopausal Women with Primary Hyperparathyroidism. Mediators of Inflammation, 2020, 2020, 1-6. | 1.4 | 1 |
| 462 | Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Progress in Retinal and Eye Research, 2021, 80, 100866. | 7.3 | 104 |
| 463 | Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52â€week results from a doubleâ€blind phase 3b trial (CLARITY). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 135-142. | 1.3 | 29 |
| 464 | Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis. Clinical Rheumatology, 2021, 40, 25-32. | 1.0 | 11 |
| 465 | Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. Clinical Rheumatology, 2021, 40, 33-41. | 1.0 | 7 |
| 466 | Axial psoriatic arthritis: An update for dermatologists. Journal of the American Academy of Dermatology, 2021, 84, 92-101. | 0.6 | 41 |
| 467 | Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placeboâ€Controlled Phase III Study. Arthritis and Rheumatology, 2021, 73, 110-120. | 2.9 | 100 |
| 468 | Understanding the paradigm of non-radiographic axial spondyloarthritis. Clinical Rheumatology, 2021, 40, 501-512. | 1.0 | 14 |
| 469 | Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52â€week results from a Phase 3 doubleâ€blind randomized, controlled trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 938-947. | 1.3 | 61 |
| 470 | Non-radiographic axial spondyloarthritis. Modern Rheumatology, 2021, 31, 277-282. | 0.9 | 9 |
| 471 | The societal impact of a biologic treatment of ankylosing spondylitis: a case study based on secukinumab. Journal of Comparative Effectiveness Research, 2021, 10, 143-155. | 0.6 | 4 |
| 472 | Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Annals of the Rheumatic Diseases, 2021, 80, 475-486. | 0.5 | 17 |
| 473 | IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. Clinical Reviews in Allergy and Immunology, 2021, 60, 31-45. | 2.9 | 14 |
| 474 | Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. Rheumatology and Therapy, 2021, 8, 273-288. | 1.1 | 11 |
| 475 | Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576. | 0.6 | 5 |
| 476 | New developments in ankylosing spondylitisâ€"status in 2021. Rheumatology, 2021, 60, vi29-vi37. | 0.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 477 | Top 100 cited articles on ankylosing spondylitis. Reumatismo, 2021, 72, 218-227. | 0.4 | 3 |
| 478 | Wirksamkeit und Sicherheit von Biologika bei Psoriasis und Psoriasis-Arthritis und ihre Auswirkungen auf KomorbiditÃten: eine LiteraturÃ¼bersicht. Karger Kompass Dermatologie, 2021, 9, 2-8. | 0.0 | 0 |
| 480 | Axial spondyloarthritis: new advances in diagnosis and management. BMJ, The, 2021, 372, m4447. | 3.0 | 71 |
| 481 | The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. Frontiers in Immunology, 2020, 11, 596086. | 2.2 | 35 |
| 482 | Psoriasis: Recent progress in molecularâ€targeted therapies. Journal of Dermatology, 2021, 48, 761-777. | 0.6 | 39 |
| 483 | Safety of secukinumab for the treatment of active ankylosing spondylitis. Expert Opinion on Drug Safety, 2021, 20, 1-8. | 1.0 | 5 |
| 484 | The paradigm of non-radiographic sacroiliitisâ€"why the ongoing doubts?. Clinical Rheumatology, 2021, 40, 443-446. | 1.0 | 0 |
| 485 | â€˜All disease begins in the gutâ€™â€"the role of the intestinal microbiome in ankylosing spondylitis. Rheumatology Advances in Practice, 2021, 5, rkab063. | 0.3 | 7 |
| 486 | Warum die Hemmung von IL-23 bei ankylosierender Spondylitis nicht wirksam war. Karger Kompass Autoimmun, 2021, 3, 100-107. | 0.0 | 0 |
| 487 | Research Progress of IL-23/IL-17 Axis in the Pathogenesis and Treatment of Axial Spondyloarthritis. Advances in Clinical Medicine, 2021, 11, 981-989. | 0.0 | 0 |
| 488 | Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00422. | 0.6 | 12 |
| 489 | The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis. Seminars in Immunopathology, 2021, 43, 235-243. | 2.8 | 18 |
| 490 | The role of ixekizumab in non-radiographic axial spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2098673. | 1.2 | 4 |
| 491 | Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110418. | 1.2 | 9 |
| 492 | Distinct roles of interleukin-17 and T helper 17Âcells among autoimmune diseases. Journal of Translational Autoimmunity, 2021, 4, 100104. | 2.0 | 16 |
| 493 | Serum Sp17 Autoantibody Serves as a Potential Specific Biomarker in Patients with SAPHO Syndrome. Journal of Clinical Immunology, 2021, 41, 565-575. | 2.0 | 0 |
| 494 | Biologic therapies for the treatment of ankylosing spondylitis. Journal of the Korean Medical Association, 2021, 64, 116-123. | 0.1 | 1 |
| 495 | Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis. European Journal of Immunology, 2021, 51, 798-810. | 1.6 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 496 | Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Frontiers in Immunology, 2021, 12, 637829. | 2.2 | 140 |
| 497 | Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie, 2021, 75, 293-303. | 0.1 | 3 |
| 498 | From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery. Frontiers in Immunology, 2021, 12, 624632. | 2.2 | 16 |
| 499 | Intestinal ulcers induced by intravesical bacillus Calmette-GuÃ©rin therapy. Modern Rheumatology Case Reports, 2021, 5, 421-424. | 0.3 | 3 |
| 500 | IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?. Frontiers in Immunology, 2020, 11, 623874. | 2.2 | 16 |
| 501 | Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet, The, 2021, 397, 754-766. | 6.3 | 222 |
| 502 | Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 624971. | 2.2 | 26 |
| 503 | Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmunity Reviews, 2021, 20, 102760. | 2.5 | 15 |
| 504 | Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis. Frontiers in Immunology, 2021, 12, 614255. | 2.2 | 28 |
| 505 | VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy. Rheumatology, 2021, 60, e314-e315. | 0.9 | 35 |
| 506 | Efficacy and safety of interleukinâ€17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 895-906. | 0.7 | 9 |
| 507 | Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies. Journal of Rheumatology, 2021, 48, 1251-1258. | 1.0 | 9 |
| 508 | Spondyloarthrite et sarcoÃ¯doseÂ: faux amis ou vÃ©ritable associationÂ? Revue systÃ©matique de la littÃ©rature. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 101-109. | 0.0 | 0 |
| 509 | Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure. Rheumatology, 2021, 60, 5743-5752. | 0.9 | 13 |
| 510 | Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Annals of the Rheumatic Diseases, 2021, 80, 1014-1021. | 0.5 | 31 |
| 511 | Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment. Sovremennaya Revmatologiya, 2021, 15, 94-105. | 0.1 | 6 |
| 512 | Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clinical Immunology, 2021, 225, 108680. | 1.4 | 23 |
| 513 | Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Review of Clinical Immunology, 2021, 17, 331-354. | 1.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 514 | Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab. ReumatologÃa ClÃnica (English Edition), 2021, 18, 25-29. | 0.2 | 1 |
| 515 | Efficacy, tolerability, patient usability, and satisfaction with a 2â€‰mL pre-filled syringe containing secukinumab 300â€‰mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. Journal of Dermatological Treatment, 2022, 33, 1718-1726. | 1.1 | 6 |
| 516 | Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World Journal of Gastroenterology, 2021, 27, 2312-2324. | 1.4 | 13 |
| 517 | Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Frontiers in Medicine, 2021, 8, 679009. | 1.2 | 27 |
| 518 | Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?. Current Opinion in Rheumatology, 2021, 33, 363-369. | 2.0 | 3 |
| 519 | Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis. Current Opinion in Rheumatology, 2021, 33, 333-340. | 2.0 | 5 |
| 520 | Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation?. Frontiers in Medicine, 2021, 8, 666772. | 1.2 | 8 |
| 521 | Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. ImmunoTargets and Therapy, 2021, Volume 10, 141-153. | 2.7 | 16 |
| 522 | Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine, 2021, 88, 105210. | 0.8 | 0 |
| 523 | JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Review of Clinical Immunology, 2021, 17, 701-715. | 1.3 | 21 |
| 524 | The road to personalised medicine in psoriatic arthritis. Expert Review of Clinical Immunology, 2021, 17, 799-802. | 1.3 | 0 |
| 525 | Tapering of Biological Agents in Juvenile ERA Patients in Daily Clinical Practice. Frontiers in Medicine, 2021, 8, 665170. | 1.2 | 4 |
| 526 | Mechanisms and Mediators of Pain in Chronic Inflammatory Arthritis. Current Treatment Options in Rheumatology, 2021, 7, 194-207. | 0.6 | 0 |
| 527 | Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis. Frontiers in Immunology, 2021, 12, 622770. | 2.2 | 21 |
| 528 | Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis. Frontiers in Immunology, 2021, 12, 691073. | 2.2 | 12 |
| 529 | Clinical and laboratory characteristics of psoriatic arthritis in a cohort of Egyptian patients. Egyptian Rheumatologist, 2021, 43, 229-234. | 0.5 | 3 |
| 530 | Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. , 2022, 229, 107925. | | 16 |
| 531 | Inhibition of ILâ€17 prevents the progression of traumatic heterotopic ossification. Journal of Cellular and Molecular Medicine, 2021, 25, 7709-7719. | 1.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 532 | Targeted Therapies in Axial Psoriatic Arthritis. Frontiers in Genetics, 2021, 12, 689984. | 1.1 | 1 |
| 533 | The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models. Frontiers in Immunology, 2021, 12, 618581. | 2.2 | 11 |
| 534 | Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?. Annals of the Rheumatic Diseases, 2021, 80, 1445-1452. | 0.5 | 21 |
| 535 | Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents. Journal of Experimental Pharmacology, 2021, Volume 13, 627-635. | 1.5 | 4 |
| 536 | Interleukinâ€17 inhibitor, is it safer than tumor necrosis factor inhibitor?. International Journal of Rheumatic Diseases, 2021, 24, 865-868. | 0.9 | 0 |
| 537 | MicroRNA-378a-3p is overexpressed in psoriasis and modulates cell cycle arrest in keratinocytes via targeting BMP2 gene. Scientific Reports, 2021, 11, 14186. | 1.6 | 8 |
| 538 | New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?. Cureus, 2021, 13, e16147. | 0.2 | 2 |
| 539 | Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four PhaseÂ3 Studies. Rheumatology and Therapy, 2021, 8, 1223-1240. | 1.1 | 6 |
| 540 | Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukinâ€17 Inhibitors: A Nationwide <scp>Populationâ€Based</scp> Study Using the French National Health Data System. Arthritis and Rheumatology, 2022, 74, 244-252. | 2.9 | 24 |
| 541 | Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Research and Therapy, 2021, 23, 192. | 1.6 | 10 |
| 542 | Analysis of Tweets Containing Information Related to Rheumatological Diseases on Twitter. International Journal of Environmental Research and Public Health, 2021, 18, 9094. | 1.2 | 12 |
| 543 | Confidence intervals for exposureâ€adjusted rate differences in randomized trials. Pharmaceutical Statistics, 2022, 21, 103-121. | 0.7 | 1 |
| 544 | Recent Updates in Juvenile Spondyloarthritis. Rheumatic Disease Clinics of North America, 2021, 47, 565-583. | 0.8 | 13 |
| 545 | Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. Expert Review of Clinical Immunology, 2021, 17, 1059-1071. | 1.3 | 2 |
| 546 | Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opinion on Drug Safety, 2022, 21, 223-239. | 1.0 | 16 |
| 547 | Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. New England Journal of Medicine, 2021, 385, 628-639. | 13.9 | 156 |
| 548 | AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2. Journal of Medicinal Chemistry, 2021, 64, 13807-13829. | 2.9 | 7 |
| 549 | Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies. Frontiers in Immunology, 2021, 12, 770275. | 2.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 550 | Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis. Frontiers in Immunology, 2021, 12, 715510. | 2.2 | 6 |
| 551 | Identification of immune related cells and crucial genes in the peripheral blood of ankylosing spondylitis by integrated bioinformatics analysis. PeerJ, 2021, 9, e12125. | 0.9 | 16 |
| 552 | Paradoxical Augmentation of Experimental Spondyloarthritis by RORC Inhibition in HLA-B27 Transgenic Rats. Frontiers in Immunology, 2021, 12, 699987. | 2.2 | 3 |
| 553 | The use of secukinumab in an HIV-positive patient with axial spondyloarthritis: a case-based review. Clinical Rheumatology, 2021, 40, 5111-5114. | 1.0 | 3 |
| 554 | A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. Journal of the American Academy of Dermatology, 2022, 86, 122-130. | 0.6 | 23 |
| 555 | Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. Atherosclerosis, 2021, 335, 98-109. | 0.4 | 8 |
| 556 | Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Research and Therapy, 2021, 23, 231. | 1.6 | 17 |
| 557 | Newâ€onset Crohn's disease after interleukinâ€17A inhibitor therapy with secukinumab: A report of an unusual case. Advances in Digestive Medicine, 0, , . | 0.1 | 1 |
| 558 | Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatology, 2021, 5, 35. | 0.6 | 2 |
| 559 | Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology, 2021, 161, 1118-1132. | 0.6 | 267 |
| 560 | Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy, 2021, 11, 385-400. | 1.4 | 29 |
| 562 | Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens. Clinics, 2021, 76, e2820. | 0.6 | 1 |
| 563 | Role of Interleukins on Physiological and Pathological Bone Resorption and Bone Formation: Effects by Cytokines in The IL-12 and IL-17 Families, and by IL-3, IL-32 and IL-34. , 2020, , 88-102. | | 1 |
| 564 | Spondyloarthritides. , 2020, , 691-701. | | 1 |
| 565 | Interleukin-17A induces vascular remodeling of small arteries and blood pressure elevation. Clinical Science, 2020, 134, 513-527. | 1.8 | 31 |
| 566 | Deletion of deltaâ€like 1 homologue accelerates renal inflammation by modulating the Th17 immune response. FASEB Journal, 2021, 35, e21213. | 0.2 | 5 |
| 568 | Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Annals of the Rheumatic Diseases, 2021, 80, 582-590. | 0.5 | 105 |
| 569 | An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight, 2017, 2, . | 2.3 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 570 | Pathophysiology of ocular toxoplasmosis: Facts and open questions. PLoS Neglected Tropical Diseases, 2020, 14, e0008905. | 1.3 | 29 |
| 571 | Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis. PLoS ONE, 2017, 12, e0171757. | 1.1 | 20 |
| 572 | IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 400-406. | 0.2 | 12 |
| 573 | Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Sovremennaya Revmatologiya, 2020, 14, 39-49. | 0.1 | 12 |
| 574 | IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis. Biomolecules, 2020, 10, 1361. | 1.8 | 12 |
| 575 | Axial spondyloarthritis. Vnitrni Lekarstvi, 2018, 64, 108-116. | 0.1 | 2 |
| 576 | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean Journal of Internal Medicine, 2020, 35, 41-59. | 0.7 | 20 |
| 577 | The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. Journal of Rheumatic Diseases, 2020, 27, 4. | 0.4 | 17 |
| 578 | Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!. Indian Journal of Rheumatology, 2020, 15, 64. | 0.2 | 2 |
| 579 | Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 376-386. | 0.2 | 10 |
| 580 | Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. European Journal of Rheumatology, 2018, 5, 216-223. | 1.3 | 8 |
| 581 | Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110514. | 1.2 | 2 |
| 582 | Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases. Chinese Medical Journal, 2021, Publish Ahead of Print, 2525-2528. | 0.9 | 2 |
| 583 | Planning a Clinical Trial Programme for Medicinal Products for the Treatment of Axial Spondyloarthritis. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2021, 11, 202-211. | 0.1 | 0 |
| 584 | Review article: drugâ€induced small bowel injury. Alimentary Pharmacology and Therapeutics, 2021, 54, 1370-1388. | 1.9 | 12 |
| 585 | Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Research and Therapy, 2021, 23, 254. | 1.6 | 10 |
| 586 | A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. Rheumatology and Therapy, 2021, 8, 1775-1787. | 1.1 | 10 |
| 587 | Neue Arzneimittel 2015. , 2016, , 49-134. | | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 588 | Spondyloarthritis. , 2016, , 1210-1221. | | 0 |
| 590 | Spondyloarthritiden. , 2017, , 41-73. | | 0 |
| 591 | The safety of secukinumab in treating psoriasis. Dermatologie Pro Praxi, 2017, 11, 178-181. | 0.1 | 1 |
| 592 | A New Medical Therapy for Axial Spondyloarthritis. Korean Journal of Medicine, 2018, 93, 424-429. | 0.1 | 0 |
| 594 | Gelenk- und Muskelschmerzen. Springer Reference Medizin, 2019, , 1-27. | 0.0 | 0 |
| 595 | Testing of monoclonal antibodies against the T-cell receptor associated with ankylosing spondylitis. Bulletin of Russian State Medical University, 2018, , 71-79. | 0.3 | 3 |
| 596 | Ð¢ÐµÑ‚Ð¸Ñ€Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð¼Ð¾Ð½Ð¾Ð¿Ð»Ð¾Ð½Ð°Ð»ÑŒÐ½Ñ‹Ñ… Ð°Ð½Ñ‚Ð¸Ñ‚ÐµÐ» Ðº Ð¢-ÐºÐ»ÐµÑ‚Ð¾Ñ‡Ð½Ð¾Ð¼Ñƒ | | |
| 597 | Gelenk- und Muskelschmerzen. Springer Reference Medizin, 2019, , 347-373. | 0.0 | 0 |
| 598 | Immunotherapy for Spondyloarthritis (SpA). , 2019, , 45-55. | | 0 |
| 601 | Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 668-677. | 0.2 | 3 |
| 602 | Colitis ulcerosa inducida por secukinumab: abriendo la caja de Pandora de la inmunidad. GastroenterologÃa Y HepatologÃa, 2020, 43, 358-359. | 0.2 | 1 |
| 603 | Estudio prospectivo multicÃ©ntrico de experiencia en prÃ¡ctica clÃnica real en el control de medidas de desenlace reportadas por el paciente (PRO) diagnosticado de artritis psoriÃ¡sica y/o espondiloartritis y que inicia tratamiento con secukinumab. ReumatologÃa ClÃnica, 2022, 18, 25-29. | 0.2 | 0 |
| 604 | Adaptive Immune-Related Cells and Cytokines in Spondyloarthropathies. , 2022, , 49-82. | | 0 |
| 605 | Update on Juvenile Spondyloarthritis. Pediatrics in Review, 2021, 42, 581-589. | 0.2 | 1 |
| 606 | Interleukin-17 inhibitors for the treatment of ankylosing spondylitis. Rheumatology and Immunology Research, 2020, 1, 25-29. | 0.2 | 0 |
| 608 | New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the caseâ€“control MISSIL study. Rheumatology, 2022, 61, 2848-2855. | 0.9 | 5 |
| 610 | Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis. Scientific Reports, 2021, 11, 21555. | 1.6 | 4 |
| 611 | Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial. Rheumatology, 2022, 61, 2856-2866. | 0.9 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 612 | The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights. Frontiers in Medicine, 2021, 8, 782150. | 1.2 | 13 |
| 613 | Secukinumab for the Treatment of Inflammatory Skin and Joint Disease. , 2021, , 243-251. | | 0 |
| 614 | Randomised, double-blind, multicentre, phase â…/â…¡ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. BMJ Open, 2020, 10, e039067. | 0.8 | 1 |
| 615 | A Road Map of the Axial Spondyloarthritis Continuum. Mayo Clinic Proceedings, 2022, 97, 134-145. | 1.4 | 5 |
| 616 | Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis. Nature Communications, 2021, 12, 6540. | 5.8 | 20 |
| 617 | SOX9+ enthesis cells are associated with spinal ankylosis in ankylosing spondylitis. Osteoarthritis and Cartilage, 2022, 30, 280-290. | 0.6 | 8 |
| 618 | Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis. Clinical Rheumatology, 2022, 41, 471-481. | 1.0 | 1 |
| 619 | Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. Rheumatology and Therapy, 2022, 9, 49-71. | 1.1 | 3 |
| 620 | Dose reduction and discontinuation of biologic and targeted syntheticÂdisease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity. The Cochrane Library, 2021, 2021, . | 1.5 | 0 |
| 621 | Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years. Rheumatology and Therapy, 2022, 9, 73-94. | 1.1 | 3 |
| 622 | Revisiting Asian chronic rhinosinusitis in the era of type 2 biologics. Clinical and Experimental Allergy, 2022, 52, 231-243. | 1.4 | 24 |
| 624 | Randomised, double-blind, multicentre, phase â…/â…¡ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. BMJ Open, 2020, 10, e039067. | 0.8 | 3 |
| 625 | Immunosuppression in Rheumatologic and Auto-immune Disease. Handbook of Experimental Pharmacology, 2021, , 181-208. | 0.9 | 2 |
| 626 | Axial spondyloarthritis. Annals of the Rheumatic Diseases, 2021, 80, 1511-1521. | 0.5 | 118 |
| 627 | Bone Involvement in Patients with Spondyloarthropathies. Calcified Tissue International, 2022, 110, 393-420. | 1.5 | 7 |
| 628 | Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis. International Journal of Molecular Sciences, 2022, 23, 859. | 1.8 | 13 |
| 629 | Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study. Frontiers in Medicine, 2021, 8, 815881. | 1.2 | 6 |
| 630 | Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2â€‰ml autoinjector in adult patients with plaque psoriasis: 52â€week results from MATURE, a randomized, placeboâ€controlled trial. Dermatologic Therapy, 2022, 35, e15285. | 0.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 631 | Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study. Dermatology and Therapy, 2022, 12, 511-527. | 1.4 | 6 |
| 632 | Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. RMD Open, 2022, 8, e002067. | 1.8 | 11 |
| 633 | Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies. Cells, 2022, 11, 515. | 1.8 | 15 |
| 634 | Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis. Modern Rheumatology, 2023, 33, 194-201. | 0.9 | 3 |
| 635 | Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Dermato-Venereologica, 2022, 102, adv00698. | 0.6 | 34 |
| 636 | No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors. Frontiers in Immunology, 2022, 13, 818413. | 2.2 | 1 |
| 637 | Oral Candida Infection in Psoriatic Patients Treated with IL17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literature. Diagnostics, 2022, 12, 3. | 1.3 | 4 |
| 639 | Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis. Inflammopharmacology, 2022, 30, 435-451. | 1.9 | 20 |
| 640 | Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized Definition. Advances in Therapy, 2022, 39, 1490-1501. | 1.3 | 12 |
| 641 | Responding to and Driving Change in Rheumatology: Report from the 12th International Immunology Summit 2021. Rheumatology and Therapy, 2022, 9, 705-719. | 1.1 | 0 |
| 643 | Treatment of axial spondyloarthritis: an update. Nature Reviews Rheumatology, 2022, 18, 205-216. | 3.5 | 56 |
| 644 | Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review. Immunotherapy, 2022, 14, 401-408. | 1.0 | 3 |
| 645 | Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials. Seminars in Arthritis and Rheumatism, 2022, 54, 151996. | 1.6 | 7 |
| 646 | Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1. BMC Musculoskeletal Disorders, 2021, 22, 1037. | 0.8 | 8 |
| 647 | Therapeutic Targets for Ankylosing Spondylitis â€“ Recent Insights and Future Prospects. Open Access Rheumatology: Research and Reviews, 2022, Volume 14, 57-66. | 0.8 | 7 |
| 661 | Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry. Rheumatology and Therapy, 2022, 9, 1031-1047. | 1.1 | 9 |
| 662 | The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A. Journal of Neuroinflammation, 2022, 19, 98. | 3.1 | 26 |
| 663 | Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210903. | 1.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 664 | Improving the design of RCTs in non-radiographic axial spondyloarthritis. Nature Reviews Rheumatology, 2022, 18, 481-489. | 3.5 | 1 |
| 665 | New Insights on Juvenile Psoriatic Arthritis. Frontiers in Pediatrics, 2022, 10, . | 0.9 | 9 |
| 666 | Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open, 2022, 8, e002253. | 1.8 | 14 |
| 667 | Achievement of clinical-laboratory and ASAS-partial remission in patients with early axial spondyloarthritis according to the ESAC cohort at the 3rd year of follow-up. Terapevticheskii Arkhiv, 2022, 94, 642-646. | 0.2 | 0 |
| 668 | Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA. Clinical Rheumatology, 2022, 41, 2863-2874. | 1.0 | 5 |
| 669 | Managing pediatric psoriasis: update on treatments and challengesâ€"a review. Journal of Dermatological Treatment, 2022, 33, 2433-2442. | 1.1 | 6 |
| 670 | Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders. Translational Research, 2022, 249, 49-73. | 2.2 | 6 |
| 671 | Comprehensive Review Exploring Novel Treatments for Psoriatic Arthritis and Axial Spondyloarthritis from 2016 to 2021. , 2022, 1, 9. | | 0 |
| 672 | Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases, 2022, 81, 1515-1523. | 0.5 | 43 |
| 673 | Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signaling pathways in spondyloarthritis. Rheumatology, 0, , . | 0.9 | 0 |
| 674 | Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the BSRBR-AS and a MetaAnalysis. Journal of Rheumatology, 2023, 50, 175-184. | 1.0 | 2 |
| 675 | Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Pharmacology, 2022, 107, 537-544. | 0.9 | 6 |
| 676 | Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms. Current Rheumatology Reports, 2022, 24, 310-320. | 2.1 | 9 |
| 677 | Differential diagnosis of inflammatory arthritis from musculoskeletal ultrasound view. Rheumatology and Immunology Research, 2022, 3, 54-60. | 0.2 | 0 |
| 678 | Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. Drugs, 2022, 82, 1151-1163. | 4.9 | 2 |
| 679 | Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases, 2023, 82, 154-160. | 0.5 | 26 |
| 680 | Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. International Journal of Rheumatic Diseases, 2022, 25, 1107-1122. | 0.9 | 2 |
| 681 | Interleukin 17 and Its Involvement in Renal Cell Carcinoma. Journal of Clinical Medicine, 2022, 11, 4973. | 1.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 682 | The role of interleukin-17 in epilepsy. Epilepsy Research, 2022, 186, 107001. | 0.8 | 4 |
| 683 | Axial Disease in Psoriatic Arthritis: how can we Define it, and does it have an Impact on Treatment?. Mediterranean Journal of Rheumatology, 2022, 33, 142. | 0.3 | 8 |
| 684 | Course and Prognosis of AA Amyloidosis in Patients with Psoriatic Arthritis: Report of Three Cases from a Single Center Cohort and Review of the Literature. Mediterranean Journal of Rheumatology, 2022, 33, 185. | 0.3 | 0 |
| 685 | Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology. Mediterranean Journal of Rheumatology, 2022, 33, 126. | 0.3 | 4 |
| 686 | Microorganisms in the Pathogenesis and Management of Ankylosing Spondylitis. , 2022, , 459-487. | | 0 |
| 689 | Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis. Rheumatology International, 2023, 43, 147-156. | 1.5 | 7 |
| 690 | Protective effect of Secukinumab on severe sepsis model rats by neutralizing IL-17A to inhibit IKBÎ±/NFÎºB inflammatory signal pathway. European Journal of Medical Research, 2022, 27, . | 0.9 | 3 |
| 691 | How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management. Current Rheumatology Reports, 2023, 25, 12-33. | 2.1 | 4 |
| 692 | Brain Interleukin-17A contributes to neuroinflammation and cardiac dysfunction in rats with myocardial infarction. Frontiers in Neuroscience, 0, 16, . | 1.4 | 1 |
| 693 | The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment. Medicina (Lithuania), 2022, 58, 1552. | 0.8 | 9 |
| 694 | Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. Journal of Rheumatology, 0, , jrheum.220309. | 1.0 | 11 |
| 695 | Single-cell profiling to transform immunotherapy usage and target discovery in immune-mediated inflammatory diseases. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 696 | Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region. BioDrugs, 2022, 36, 781-789. | 2.2 | 2 |
| 697 | Tc17 cells in autoimmune diseases. Chinese Medical Journal, 2022, 135, 2167-2177. | 0.9 | 4 |
| 698 | Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients. International Journal of Environmental Research and Public Health, 2022, 19, 15861. | 1.2 | 1 |
| 699 | Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 594-601. | 0.2 | 1 |
| 700 | Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis. Expert Opinion on Biological Therapy, 2023, 23, 195-206. | 1.4 | 3 |
| 701 | Axial Spondyloarthritis: Reshape the Futureâ€"From the â€œ2022 GISEA International Symposiumâ€• Journal of Clinical Medicine, 2022, 11, 7537. | 1.0 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 702 | Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatology and Therapy, 0, , . | 1.4 | 0 |
| 703 | The star target in SLE: IL-17. Inflammation Research, 2023, 72, 313-328. | 1.6 | 6 |
| 704 | Novel therapies in axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101811. | 1.4 | 1 |
| 705 | Resveratrol Attenuates Ankylosing Spondylitis in Mice by Inhibiting the TLR4/NF-ÎºB/NLRP3 Pathway and Regulating Gut Microbiota. Immunological Investigations, 2023, 52, 194-209. | 1.0 | 4 |
| 706 | Chronic Recurrent Multifocal Osteomyelitis (CRMO) and Juvenile Spondyloarthritis (JSpA): To What Extent Are They Related?. Journal of Clinical Medicine, 2023, 12, 453. | 1.0 | 3 |
| 707 | Fine-Tuning the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway. European Medical Journal Rheumatology, 0, , 61-70. | 0.0 | 0 |
| 708 | Seronegative spondyloarthropathy-associated inflammatory bowel disease. World Journal of Gastroenterology, 0, 29, 450-468. | 1.4 | 2 |
| 709 | Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network. Journal of Rheumatology, 2023, 50, 634-640. | 1.0 | 1 |
| 710 | Sixteen syndrome: a rare presentation of central demyelination. BMJ Case Reports, 2023, 16, e250440. | 0.2 | 0 |
| 711 | TH17 cell heterogeneity and its role in tissue inflammation. Nature Immunology, 2023, 24, 19-29. | 7.0 | 38 |
| 712 | Biologics in pediatric psoriasis. Journal of Dermatology, 2023, 50, 415-421. | 0.6 | 3 |
| 713 | Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation. Hormone and Metabolic Research, 2023, 55, 7-24. | 0.7 | 1 |
| 714 | Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. British Journal of Dermatology, 2023, 188, 198-207. | 1.4 | 7 |
| 715 | Evaluation of the measurement of tendon and ligament thicknesses and the presence of enthesitis in lower extremities in female patients with acne vulgaris: a randomized controlled trial. Journal of Medicine and Palliative Care:, 2022, 3, 354-358. | 0.0 | 0 |
| 716 | Spondyloarthritis. , 2016, , 1-12. | | 0 |
| 717 | Peptidomics analysis of plasma in patients with ankylosing spondylitis. Frontiers in Immunology, 0, 14, . | 2.2 | 3 |
| 718 | Secukinumab and Black Garlic Downregulate OPG/RANK/RANKL Axis and Devitalize Myocardial Interstitial Fibrosis Induced by Sunitinib in Experimental Rats. Life, 2023, 13, 308. | 1.1 | 1 |
| 719 | Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonists. ACS Medicinal Chemistry Letters, 2023, 14, 191-198. | 1.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 720 | Autoimmune diseases. , 2023, , 123-244. | | 2 |
| 721 | Interleukin 27 is a novel cytokine with anti-inflammatory effects against spondyloarthritis through the suppression of Th17 responses. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 722 | Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats. RMD Open, 2023, 9, e002851. | 1.8 | 0 |
| 723 | Purine metabolites promote ectopic new bone formation in ankylosing spondylitis. International Immunopharmacology, 2023, 116, 109810. | 1.7 | 1 |
| 724 | Analysis of <scp>Singleâ€Cell</scp> Transcriptome and Surface Protein Expression in Ankylosing Spondylitis Identifies <scp>OX40</scp>â€Positive and <scp>Glucocorticoidâ€Induced</scp> Tumor Necrosis Factor Receptorâ€“Positive Pathogenic Th17 Cells. Arthritis and Rheumatology, 2023, 75, 1176-1186. | 2.9 | 5 |
| 725 | Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic Implications. International Journal of Molecular Sciences, 2023, 24, 3957. | 1.8 | 5 |
| 726 | Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study. Clinical Rheumatology, 0, , . | 1.0 | 0 |
| 727 | Efficacy and safety of IL inhibitors, TNF-Î± inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis. Annals of Translational Medicine, 2023, 11, 178-178. | 0.7 | 4 |
| 728 | Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences, 2023, 24, 4901. | 1.8 | 15 |
| 729 | Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC). Rheumatology Advances in Practice, 2022, 7, . | 0.3 | 0 |
| 730 | Safety, Tolerability, and Pharmacokinetics of IMUâ€935, a Novel Inverse Agonist of Retinoic Acid Receptorâ€“Related Orphan Nuclear Receptor Î³t: Results From a Doubleâ€Blind, Placeboâ€Controlled, Firstâ€inâ€Human Phase 1 Study. Clinical Pharmacology in Drug Development, 2023, 12, 525-534. | 0.8 | 1 |
| 731 | Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions. Cells, 2023, 12, 972. | 1.8 | 2 |
| 732 | Targeted Therapies in Psoriatic Arthritisâ€”An Update. International Journal of Molecular Sciences, 2023, 24, 6384. | 1.8 | 5 |
| 733 | Axial Spondyloarthritis. , 2023, , 87-96. | | 0 |
| 734 | Uncovering the Underworld of Axial Spondyloarthritis. International Journal of Molecular Sciences, 2023, 24, 6463. | 1.8 | 6 |
| 735 | Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four PhaseÂ3 Clinical Trials. Advances in Therapy, 2023, 40, 2439-2456. | 1.3 | 5 |
| 736 | Cytokines and intestinal epithelial permeability: A systematic review. Autoimmunity Reviews, 2023, 22, 103331. | 2.5 | 7 |
| 737 | Biologic Response Modifiers. , 2023, , 1089-1101. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 738 | Identification immune response genes in psoriasis after treatment with secukinumab. BMC Medical Genomics, 2023, 16, . | 0.7 | 0 |
| 739 | Musculoskeletal Disorders. Medical Radiology, 2023, , . | 0.0 | 0 |
| 775 | Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older Patients. Drugs and Aging, 2023, 40, 1101-1112. | 1.3 | 0 |